FR2829498B1 - Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins - Google Patents

Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins

Info

Publication number
FR2829498B1
FR2829498B1 FR0111736A FR0111736A FR2829498B1 FR 2829498 B1 FR2829498 B1 FR 2829498B1 FR 0111736 A FR0111736 A FR 0111736A FR 0111736 A FR0111736 A FR 0111736A FR 2829498 B1 FR2829498 B1 FR 2829498B1
Authority
FR
France
Prior art keywords
igf
feline
retroviruses
vaccine adjuvant
especially against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0111736A
Other languages
English (en)
Other versions
FR2829498A1 (fr
Inventor
Christine Michele Pie Andreoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Original Assignee
Merial SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0111736A priority Critical patent/FR2829498B1/fr
Application filed by Merial SAS filed Critical Merial SAS
Priority to CA2459769A priority patent/CA2459769C/fr
Priority to US10/238,114 priority patent/US7326417B2/en
Priority to JP2003526958A priority patent/JP2005516587A/ja
Priority to AT02755576T priority patent/ATE493146T1/de
Priority to EP02755576A priority patent/EP1425305B1/fr
Priority to DE60238773T priority patent/DE60238773D1/de
Priority to PCT/IB2002/003638 priority patent/WO2003022886A1/fr
Publication of FR2829498A1 publication Critical patent/FR2829498A1/fr
Application granted granted Critical
Publication of FR2829498B1 publication Critical patent/FR2829498B1/fr
Priority to US11/963,085 priority patent/US20080181912A1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0111736A 2001-09-11 2001-09-11 Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins Expired - Lifetime FR2829498B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR0111736A FR2829498B1 (fr) 2001-09-11 2001-09-11 Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
US10/238,114 US7326417B2 (en) 2001-09-11 2002-09-10 IGF-1 as feline vaccine adjuvant, in particular against feline retroviruses
JP2003526958A JP2005516587A (ja) 2001-09-11 2002-09-10 特にネコレトロウイスルに対する、ネコワクチンアジュバントとしてのｉｇｆ−１
AT02755576T ATE493146T1 (de) 2001-09-11 2002-09-10 Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
CA2459769A CA2459769C (fr) 2001-09-11 2002-09-10 Igf-1 utilise comme adjuvant de vaccin felin, notamment contre les retrovirus felins
EP02755576A EP1425305B1 (fr) 2001-09-11 2002-09-10 Igf-1 utilise comme adjuvant de vaccin felin, notamment contre les retrovirus felins
DE60238773T DE60238773D1 (de) 2001-09-11 2002-09-10 Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
PCT/IB2002/003638 WO2003022886A1 (fr) 2001-09-11 2002-09-10 Igf-1 utilise comme adjuvant de vaccin felin, notamment contre les retrovirus felins
US11/963,085 US20080181912A1 (en) 2001-09-11 2007-12-21 Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0111736A FR2829498B1 (fr) 2001-09-11 2001-09-11 Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins

Publications (2)

Publication Number Publication Date
FR2829498A1 FR2829498A1 (fr) 2003-03-14
FR2829498B1 true FR2829498B1 (fr) 2003-11-28

Family

ID=8867163

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0111736A Expired - Lifetime FR2829498B1 (fr) 2001-09-11 2001-09-11 Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins

Country Status (7)

Country Link
EP (1) EP1425305B1 (fr)
JP (1) JP2005516587A (fr)
AT (1) ATE493146T1 (fr)
CA (1) CA2459769C (fr)
DE (1) DE60238773D1 (fr)
FR (1) FR2829498B1 (fr)
WO (1) WO2003022886A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
EP2813281B1 (fr) 2004-01-07 2016-08-17 Pall Technology UK limited Récipient pour le traitement biologique
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP2186823A1 (fr) 2005-11-14 2010-05-19 Merial Limited Thérapie génique pour traiter l'insuffisance rénale
US8603808B2 (en) 2008-05-08 2013-12-10 Merial Limited Leishmania vaccine using sand fly salivary immunogen
SI2734230T1 (sl) 2011-07-20 2019-04-30 Merial Limited Rekombinantno cepivo proti virusu mačje levkemije, ki vsebuje optimiziran gen ovojnice virusa mačje levkemije
EP2827897B1 (fr) 2012-03-20 2018-10-31 Merial, Inc. Vaccin contre l'herpèsvirus équin 1 recombinant contenant une glycoprotéine c mutée et utilisations associées
CN111848785B (zh) * 2020-07-10 2022-09-06 青岛博隆基因工程有限公司 猫疱疹病毒抗体序列、四肽链分子、免疫球蛋白分子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189481B1 (fr) * 1984-07-13 1991-01-23 Chiron Corporation Facteur de Croissance II analogue à l'Insuline
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
WO1993023067A1 (fr) * 1992-05-08 1993-11-25 Thomas Jefferson University Analogues du facteur igf-1
AU1439095A (en) * 1993-12-15 1995-07-03 Thomas Jefferson University Igf-1 analogs
GB9605124D0 (en) * 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
CA2274314C (fr) * 1996-12-02 2007-03-13 Genemedicine, Inc. Systeme d'expression du facteur de croissance insulinoide i (igf-i) et ses methodes d'utilisation
GB9926968D0 (en) * 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders

Also Published As

Publication number Publication date
CA2459769C (fr) 2013-05-28
JP2005516587A (ja) 2005-06-09
WO2003022886A1 (fr) 2003-03-20
EP1425305B1 (fr) 2010-12-29
ATE493146T1 (de) 2011-01-15
EP1425305A1 (fr) 2004-06-09
DE60238773D1 (de) 2011-02-10
CA2459769A1 (fr) 2003-03-20
FR2829498A1 (fr) 2003-03-14

Similar Documents

Publication Publication Date Title
Kuate et al. Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies
ES2753854T3 (es) Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de los mismos
Mazumder et al. Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice
ES2638577T3 (es) Vectores adenovirales que codifican un patógeno o antígeno tumoral
CY1110359T1 (el) Εμβολια με βαση σιρκοϊους χοιρων
NO992369L (no) Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
CA2408328A1 (fr) Polypeptides immunogeniques codes par des minigenes mage et leurs utilisations
WO2004050856A3 (fr) Vaccins a adn polyvalents contre la glycoproteine du vih-1 primaire et procedes de vaccination
AU2003266950A1 (en) INFECTIOUS cDNA OF AN APPROVED VACCINE STRAIN OF MEASLES VIRUS, USE FOR IMMUNOGENIC COMPOSITIONS
EP2290091A3 (fr) Virus de la rougeole recombinants exprimant des epitopes d' antigenes de virus à ARN et utilisation des virus recombinants pour la preparation de vaccins
BR9814204A (pt) "obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral"
WO2005081716A3 (fr) Vaccins adn ciblant des antigenes du coronavirus du syndrome respiratoire aigu severe (sars-cov)
BR0206823A (pt) Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
ES2439954T3 (es) Vectores víricos recombinantes para la prevención y la protección contra la infección por alfavirus
AU6683400A (en) Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat
Zeng et al. Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-Like protein in mice
Wang et al. Immunogenicity of a bovine viral diarrhea virus E2–C3d fusion protein containing a bovine homolog of C3d
KR101937792B1 (ko) 신규한 재조합 항원 단백질을 포함하는 구제역 백신 조성물
DK177298B1 (en) Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and their Use as Vaccines
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
FR2825280B1 (fr) Vaccination contre le virus de l'immunodeficience feline
WO2003029285A3 (fr) Identification de nouveaux epitopes cd8 des proteines du vih-1 presentant des proprietes therapeutiques et vaccinales contre les infection par le vih
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20